Next-Generation Thrombectomy

Focused on providing effective and easy-to-use clot removal to efficiently treat venous thromboembolisms

3

Venous Thromboembolism
(VTE)

Human Body

Deep Vein Thrombosis (DVT)

Blood clot in a deep vein, usually in the leg

Deep Vein Thrombosis
Pulmonary Embolism

Pulmonary Embolism (PE)

Blood clot travels from the leg to the lung, blocking flow

900K cases

in the U.S. each year1

100K deaths

in the U.S. each year1

3rd leading

cardiovascular cause of death behind heart attack and stroke2

Limitations with current treatments:

Thrombolytics

  • High Bleeding Risk
  • Requires ICU Monitoring
  • Lengthy treatment time before symptoms subside
  • Doesn’t address high-risk emergent situations

Mechanical Thrombectomy Devices

  • Inefficient
  • Procedurally Complex
  • Blood Loss
  • Difficulty reaching target
Three Icons

Our Solution

Simplifying Thrombectomy

Icon of Clot being broken up

Efficient Clot Removal

Catheter collects and breaks up large, mixed morphology clots

Icon of Catheter

Single-pass Procedure

Low-profile catheter navigates tortuous anatomy without crossing the clot

Icon of Person and Checkmark

Easy to Use

Simple setup with compact equipment

Company

Akura Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

Murali Srivathsa

Murali Srivathsa

President & CEO

David Voris

David Voris

Chief Financial Officer

Aadel Al-Jadda

Aadel Al-Jadda

Co-Founder & VP of R&D

Joann Heberer

Joann Heberer

Senior Vice President
QA, RA, CA

Amr Salaheih

Amr Salahieh

Co-Founder and Chairman

Mariam Maghribi

Mariam Maghribi

Chief Business Officer

Debbie White

Debbie White

SVP Human Resources

Robert Edesess

Robert Edesess

Vice President,
Intellectual Property

Interested in joining the team?

View open positions with Akura Medical and Shifamed’s other portfolio companies.

Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.

News

Akura Medical, A Shifamed Portfolio Company, Appoints Murali Srivathsa as President and CEO

CAMPBELL, CA – April 19, 2022 – Akura Medical, Inc., a Shifamed portfolio company, announced today that seasoned medtech executive, Murali Srivathsa, has joined as President and CEO. With over two decades of industry experience, Murali brings a wealth of medical device and senior leadership expertise. He joins as the team finalizes product development of its next-generation thrombectomy device.

read more

Akura Medical, A New Shifamed Portfolio Company, Closes $25M in an Oversubscribed Series A1 Financing

CAMPBELL, CA – January 10, 2022 – Akura Medical, Inc., a Shifamed portfolio company, announced today the closing of its $25M Series A1 financing, which will be used to support the development of its next-generation thrombectomy device. The financing was led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), PA MedTech VC Fund and Shifamed angel investors.

read more